FGFR2 rs10886902: Understanding Genetic Associations and Prostate Health
The rs10886902 variant is a single nucleotide polymorphism located within the FGFR2 gene. Research has identified statistical associations between this genetic marker and variations in prostate cancer aggressiveness and serum prostate-specific antigen (PSA) levels.
What each genotype means
Baseline risk profile
This genotype represents the common baseline state for this variant in the FGFR2 gene. Research indicates that individuals with this genotype do not carry the specific allele associated with increased prostate cancer aggressiveness or elevated PSA levels in certain populations. Please note that genetic risk is complex and influenced by many factors beyond a single variant.
This is the most common genotype observed across most global populations.
Increased risk association
Carrying one copy of this variant is statistically associated with a higher likelihood of elevated serum PSA levels and potentially more aggressive prostate cancer phenotypes in some studies. This association is based on population-level data and does not predict an individual health outcome. You should discuss your overall prostate health and screening needs with your clinician.
This genotype is found at moderate frequencies in many populations, though exact prevalence varies by ancestry.
Elevated risk association
Carrying two copies of this variant is statistically linked to a stronger association with prostate cancer aggressiveness and higher serum PSA levels compared to those without the variant. These findings are derived from large-scale association studies and represent a statistical trend rather than a diagnostic result. It is recommended to consult with a healthcare provider regarding appropriate prostate health monitoring.
This genotype is less common than the homozygous reference state but is present across diverse ancestral groups.
What is rs10886902?
The rs10886902 variant is a specific change in the DNA sequence, known as a single nucleotide polymorphism (SNP), located within the FGFR2 gene. In the context of human genetics, a SNP represents a variation at a single position in the DNA chain, where one nucleotide is replaced by another. This particular variant is found in a region of the genome that has been extensively studied for its potential influence on various biological traits. Because the human genome is vast, researchers use these specific identifiers, like rs10886902, to pinpoint exact locations on chromosomes to study how inherited differences might correlate with health outcomes. It is important to understand that the presence of a specific SNP does not mean an individual will develop a particular condition; rather, it indicates a statistical correlation observed in large-scale population studies. Scientists analyze these markers to better understand the complex interplay between our genetic code and the physiological processes that occur within our bodies throughout our lives.
The Role of the FGFR2 Gene
The FGFR2 gene encodes the Fibroblast Growth Factor Receptor 2 protein, which is a member of the receptor tyrosine kinase family. This protein plays a critical role in normal development, tissue homeostasis, and cellular signaling. By binding to specific growth factors, FGFR2 helps regulate essential processes such as cell proliferation, differentiation, and migration. Because of its central role in these fundamental cellular activities, the gene is highly active in various tissues throughout the body. When the function of FGFR2 is altered, it can influence how cells grow and respond to their environment. In some contexts, research has shown that FGFR2 can act as an oncogene, potentially contributing to the development or progression of certain cancers, while in other biological settings, it may function differently. Understanding the normal function of this gene provides the necessary context for why variations within or near this gene are of interest to researchers investigating cancer biology and other complex health traits.
Research and Statistical Associations
The association between rs10886902 and prostate health is primarily derived from genome-wide association studies (GWAS). These studies compare the genomes of large groups of people to identify markers that appear more frequently in individuals with a specific trait or condition. Research has suggested that this variant is correlated with prostate cancer aggressiveness and levels of serum prostate-specific antigen (PSA). It is crucial to note that the evidence strength for these associations is considered moderate. This means that while a statistical link has been observed, the biological mechanism explaining how this specific SNP influences prostate cancer risk is not fully understood. Furthermore, genetic associations are often influenced by environmental factors, lifestyle, and other genetic variants. Because these findings are based on population-level data, they cannot be used to predict an individual's specific health outcome. The complexity of cancer development means that genetic markers are only one piece of a much larger puzzle, and they should not be interpreted as a diagnostic tool for any individual.
Interpreting Your Genetic Information
When you encounter information about genetic variants like rs10886902, it is important to maintain a clear perspective on what this data means. Genetic testing results provide information about your DNA sequence, but they do not provide a medical diagnosis. The associations discussed in scientific literature are based on averages across large populations and may not apply to your personal health situation. If you have concerns about prostate health or your family history, the most appropriate course of action is to consult with a healthcare professional, such as a primary care physician or a urologist. They can provide context based on your clinical history, physical examinations, and other diagnostic tests. Never make changes to your health management or medical decisions based solely on information about a single genetic variant. Genetic information is a tool for scientific understanding, but it is not a substitute for professional medical advice, screening, or personalized care provided by a qualified clinician who understands your full health profile.
How common is this variant?
The rs10886902 variant is considered a common SNP, with its various genotypes appearing frequently across diverse global populations.
Frequently asked questions
Does having the rs10886902 variant mean I will get prostate cancer?
No, having this variant does not mean you will develop prostate cancer. It is a genetic marker associated with a statistical difference in risk at a population level, not a diagnostic test for an individual.
What is the role of PSA levels in this context?
Serum PSA is a protein produced by the prostate gland. Research has linked this variant to variations in PSA levels, which are often used in clinical settings to screen for prostate issues, though PSA levels can be influenced by many factors beyond genetics.
Should I get tested for this SNP?
Genetic testing for specific SNPs like rs10886902 is generally not recommended for routine clinical care. If you are concerned about prostate cancer, discuss appropriate screening options with your doctor based on your age, family history, and other risk factors.
Where can I find more information about FGFR2?
You can find reliable information about the FGFR2 gene and its biological functions through resources like MedlinePlus Genetics or the National Center for Biotechnology Information (NCBI) Gene database.
Sources & further reading
Educational information only, last refreshed 10/1/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs10886902?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in FGFR2
Intronic variant in FGFR2 associated with increased risk of estrogen receptor-positive breast cancer.
This SNP is associated with an increased susceptibility to breast cancer.
This variant is associated with an increased risk of breast cancer in various populations.
One of the strongest common genetic risk factors for breast cancer.
This intronic variant in the FGFR2 gene has been associated with susceptibility to BRCA2-related breast cancer.
Correlated genetic marker in the FGFR2 locus associated with altered prostate-specific antigen (PSA) levels and prostate cancer risk.